GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025
Shots:
- The P-III (ANCHOR-1: N=271, ANCHOR-2: N=257) trial assessed depemokimab + SoC vs PBO + SoC in CRSwNP pts that showed early benefits lasting over 52wks. ANCHOR data with SWIFT-1 & 2 trial data will support global filings for asthma with type 2 inflammation & CRSwNP
- Pooled analysis of 2EPs showed 0.7-point NPS decrease (-0.9 to -0.4) at 52wks. & 0.24-point VRS decrease (-0.39 to -0.08) over 49-52wks., with notable changes in rhinorrhoea & loss of smell VRS, plus Lund-Mackay CT, & SNOT-22 scores
- Analysis also showed that 74% (n=200) vs 64% (n=164) pts avoided SCS, surgery, or DMTs, while 88% (n=239) vs 83% (n=213) avoided surgery or medication by 52wks. Data was published in The Lancet
Ref: GSK | Image: GSK
Related News:- GSK Reports the China’s NMPA Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
